Skip to Content

Reproductive Safety of Novel Small Molecules in IBD

In this MEDtalk, Dr. Christian Selinger presents a systematic review that his research group conducted into reproductive safety issues of novel small molecules for the treatment of inflammatory bowel disease. The study aimed to describe the reproductive outcomes of the JAK inhibitors tofacitinib, filgotinib, and upadacitinib and the S1P inhibitor ozanimod regarding their effects on pregnancy outcomes.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top